Berlin-based AMBOSS, a leading resource for medical education and clinical decision-making in Germany and the US, closed a €240 million financing round, supporting the exploration of additional international markets and the expansion of its offering to nurses and other health care professionals.
The funding was led by new primary investors KIRKBI, M&G Investments and Lightrock with participation from existing shareholders including Partech.
In 2024, AMBOSS acquired Novaheal, a startup in the nursing field, and NEJM Knowledge+, a board exam prep product for residents in the US.
“We choose investors who are committed to our long-term vision and very flexible in the investment duration. Many of our new investors manage evergreen funds and plan to accompany us until a possible IPO and beyond,” commented Benedikt Hochkirchen, Co-founder and Co-CEO of AMBOSS. “Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy.”
Founded in 2012 by a team of physicians, AMBOSS is a global medical knowledge platform changing the way medical know-how is acquired and utilised at the point of care. With an emphasis on precise, high-quality content, innovative AI-empowered technology, and a user-centered approach, the company has grown its international team to over 500 employees from more than 50 countries, including scientists, software engineers, and 150+ physicians.
AMBOSS currently has more than 1 million professional users across 180 countries.
The concept is simple: Medical experts distill relevant medical knowledge, and AI-supported technology places it directly at users’ fingertips.
According to AMBOSS, doctors worldwide rely on them to continuously combine the latest, trusted medical content with cutting-edge technology. “Technology will not replace health care professionals, but those who embrace it will lead the way,” added Dr Madjid Salimi, Co-founder and Co-CEO of AMBOSS.
Key figures provided by AMBOSS:
- Every second inpatient treatment in Germany is reportedly carried out by a physician supported by AMBOSS.
- In the US, the “majority of medical students” use AMBOSS to successfully prepare for exams, and score higher than with other question banks.
- 25% of first-year US residents depend on AMBOSS to help them provide excellent patient care.
Key to this success is strong in-house collaboration between experienced medical experts and technology specialists.
Providing precise and actionable recommendations on diagnostics and treatment based on the latest guidelines, AMBOSS is a digital co-pilot for everyday clinical practice, potentially saving time and avoiding treatment errors.
Peter Bason, Head of Private Capital at KIRKBI, says, “We have followed AMBOSS’ impressive growth journey, from its successful US expansion to its strong focus on innovation. Its unique platform is becoming a vital tool for both medical students and health care professionals, supporting learning and decision-making at every stage. We are excited to partner with other experienced technology and growth investors to back AMBOSS’ visionary leadership team in their mission of empowering the next generation of health care professionals worldwide.”
Read the orginal article: https://www.eu-startups.com/2025/03/amboss-raises-e240-million-to-expand-position-as-leading-co-pilot-for-physicians-worldwide/
